pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

445 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT780Endpoints580BioPharma Dive224onclive165BioSpace56Fierce Biotech54raps24
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies
    <p>The future of medicine is here. See how specialized logistics are saving lives with next-gen cell and gene therapies.</p>
    BioPharma Dive · 2mo ago↗ source
  • The capacity crunch in biopharma is a location problem
    <p>Cell and gene therapies aren’t limited by ideas—they’re limited by where they’re built. See how “ready-now” locations change the math on scaling.</p>
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Nivolumab Plus SOC Therapy Shows Encouraging Disease Control in Grade Group 5 Prostate Cancer]]>
    <![CDATA[The regimen produced a 2-year freedom from biochemical recurrence rate of 90.3% in grade group 5 prostate cancer.]]>
← prev
page 14 of 18
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
onclive · 2mo ago
↗ source
  • <![CDATA[Five Under 5: Top Oncology Videos for the Week of 5/3]]>
    <![CDATA[The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[ADCs Reshape the Future of Lung Cancer Care: From Second-Line Therapy to Earlier Intervention]]>
    <![CDATA[Judy Wang, MD, discusses how ADCs are transforming NSCLC treatment with improved responses, biomarker-driven care, and CNS activity.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[The OncFive: Top Oncology Articles for the Week of 5/3]]>
    <![CDATA[The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT]]>
    <![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer]]>
    <![CDATA[Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma]]>
    <![CDATA[Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Biomarker-Directed Therapies Move the GI Oncology Paradigm Beyond a One-Size-Fits-All Approach: With Michael J. Pishvaian, MD, PhD]]>
    <![CDATA[Michael J. Pishvaian, MD, PhD discusses how biomarker-directed strategies, including HER2, CLDN18.2, and KRAS inhibition, are transforming GI cancer care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Capivasertib/Fulvestrant Yields Numerical OS Advantage in PIK3CA/AKT1/PTEN–Altered Breast Cancer]]>
    <![CDATA[Capivasertib plus fulvestrant generated a numerical OS benefit vs placebo plus fulvestrant in PIK3CA/AKT1/PTEN-altered advanced breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Approves Zenocutuzumab for NRG1 Fusion+ Cholangiocarcinoma ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[UT MD Anderson Shares Latest Research Breakthroughs]]>
    <![CDATA[The University of Texas MD Anderson Cancer Center released recent oncology research highlights.]]>
    onclive · 2mo ago↗ source
  • Lilly to invest extra $4.5B across Indiana manufacturing
    <figure><div><img src="https://imgproxy.divecdn.com/8nTrHlsFTcngJswJxr_8afos9dxh_YxQE6LZmgMA2_I/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMDkyNDczMjEzX2VHa…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Giants of Cancer Care Announces the 14th Annual Class of Inductees ]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[OncLive Weekly News Quiz (5/8/2026): Test Your Knowledge on Key Breast, Lung, and Pancreatic Cancer Updates]]>
    <![CDATA[Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026]]>
    <![CDATA[Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026]]>
    <![CDATA[Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.]]>
    onclive · 2mo ago↗ source
  • FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 2mo ago↗ source
  • Lilly, Gilead lead pharma’s M&A boom
    <figure><div><img src="https://imgproxy.divecdn.com/wW2Sw-v1m2RoAnzb6Llg6MP71MxLlDb61aNlxns-F98/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjIxODc5NzA5X2RKS…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL]]>
    <![CDATA[Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[The PYNNACLE Phase 2 trial assessing rezatapopt, a selective p53 reactivator, in patients with advanced or metastatic solid tumors harboring a TP53 Y220C mutation: Interim analysis of patients with ovarian cancer]]>
    <![CDATA[Alison Schram, MD, discusses interim PYNNACLE phase 2 data showing that single-agent rezatapopt produced clinically meaningful responses and a manageable safety profile in heavily pretreat…
    onclive · 2mo ago↗ source
  • <![CDATA[Characterization and Management of Sevabertinib induced Diarrhea in the SOHO 1 study ]]>
    <![CDATA[This analysis from the SOHO-01 study evaluated the safety profile of sevabertinib in HER2-mutated non–small cell lung cancer, with a specific focus on treatment-related diarrhea. Diarrhea…
    onclive · 2mo ago↗ source
  • <![CDATA[First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC]]>
    <![CDATA[Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerability]]>
    <![CDATA[This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and st…
    onclive · 2mo ago↗ source